In October, Eli Lillys Zepbound and Mounjaro were removed from the drug shortage list after nearly two years, though the FDA warned that there still may be intermittent localized supply disruptions. The removal from the listwhich bars outsourcing facilities from producing compounded versionsspurred the Outsourcing Facilities Association to file a lawsuit against the FDA, saying the move will deprive much of the public of access to a needed medicine. In response, the FDA agreed to reevaluate the situation and will allow compounding to continue during this period
The average age of the participants was 42 11 years, and there were more men (73.6%) than women
There is a slight discoloration if you look closely, but no raised scarring, no texture issues
Your GLP-1 symptoms are not my GLP-1 symptoms Nausea gets most of the airtime when people talk about GLP-1 side effects
Las referencias a Wegovy, Ozempic, Rybelsus, Mounjaro, Saxenda u otras marcas de GLP-1 son solo informativas